SCHEMBL8964294

SCHEMBL8964294

O=C(c1cncc(Br)c1)c1cccc(N2CCCN(Cc3ccccc3)CC2)n1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CASP1 P29466 2/20 0.48
CASP5 P51878 2/20 0.48
CASP4 P49662 1/20 0.48
HSD11B1 P28845 1/20 0.44
HTT P42858 3/20 0.43
ALDH1A1 P00352 3/20 0.43
KDM4E B2RXH2 1/20 0.43
ALOX15 P16050 1/20 0.43
HRH3 Q9Y5N1 1/20 0.43
NPC1 O15118 1/20 0.43
RAB9A P51151 1/20 0.43
HSD17B14 Q9BPX1 1/20 0.42
SCN9A Q15858 1/20 0.41
MAPT P10636 2/20 0.40
CYP3A4 P08684 1/20 0.40
CYP2D6 P10635 1/20 0.40
MAPK1 P28482 1/20 0.40
CYP2C19 P33261 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
USP2 O75604 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8964479 0.91 CASP1 (0.47) CASP1CASP5CASP4HTTALDH1A1
SCHEMBL8964520 0.88 HTT (0.49) HSD11B1HTTALDH1A1KDM4EALOX15
SCHEMBL8964288 0.87 PIM1 (0.45) HTTALDH1A1KDM4EALOX15NPC1
SCHEMBL8964942 0.85 MAPT (0.52) CASP1CASP5CASP4HSD11B1HTT
SCHEMBL8963994 0.85 GBA1 (0.48) HSD11B1HTTALDH1A1KDM4EALOX15
SCHEMBL8964454 0.85 HSD17B14 (0.42) CASP1CASP5CASP4HSD11B1HTT
SCHEMBL8964552 0.85 HSD17B14 (0.42) HSD11B1HTTALDH1A1KDM4EALOX15
SCHEMBL8964080 0.83 CACNA1I (0.48) HTTALDH1A1KDM4EALOX15NPC1
SCHEMBL8964776 0.83 ALDH1A1 (0.46) CASP1CASP5CASP4HTTALDH1A1
SCHEMBL9008398 0.83 PRKCQ (0.50) CASP1CASP5CASP4HSD11B1HRH3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140221334-A1 KINASE INHIBITORS VERTEX PHARMACEUTICALS INCORPORATED (US) 2014-08-07 US disclosed
US-8741931-B2 Kinase inhibitors VERTEX PHARMACEUTICALS INCORPORATED 2014-06-03 US disclosed
US-20120214799-A1 KINASE INHIBITORS VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-08-23 US disclosed
US-8188071-B2 Amino substituted pyridines as potent kinase inhibitors VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-05-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140221334-A1 KINASE INHIBITORS MAP3K20, MAP3K1, MAP3K6 CASP1 3960/4885CASP5 2890/4885CASP4 4287/4885
US-20120214799-A1 KINASE INHIBITORS MAP3K20, MAP3K1, MAP3K6 CASP1 3960/4885CASP5 2890/4885CASP4 4287/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.